-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 17, Sinovation, China Antibody and Genting Shinya announced that they have reached an exclusive global cooperation agreement, granting Genting Shinya the right to develop and commercialize XNW1011 (SN1011) worldwide in the field of kidney disease
.
XNW1011 is a new generation of covalent and reversible BTK inhibitor independently developed by Sinoville.
It is undergoing clinical trials for tumor indications and is jointly conducting clinical research on autoimmune diseases with Chinese antibodies
.
XNW1011 is currently preparing to carry out phase II clinical trials for multiple indications
This cooperation agreement with Everest has a down payment of 12 million U.